{ "abstract": "Background: The expanding landscape of CD19-directed therapies for diffuse large B-cell lymphoma (DLBCL), including tafasitamab (tafa) and chimeric antigen receptor T-cell (CAR-T), is promising for patients (pts). However, there exist theoretical concerns that prior exposure to anti-CD19 therapy may compromise the efficacy of subsequent treatment with CAR-T. Several studies have demonstrated retention of CD19 expression following tafa, with limited evidence on the effectiveness and safety of sequential use of CAR-T post tafa. Aim: To assess effectiveness and safety of CAR-T post tafa among adult pts with relapsed/refractory (R/R) DLBCL. Materials and methods: A retrospective, US and EU panel-based chart review collected data for adults with R/R DLBCL who received tafa (± lenalidomide) and also subsequent CAR-T (index date) in second-line (2L)/3L/4L. Pts had to have ≥6 months of follow-up post CAR-T (except in the event of death); pts were followed until the start of new anticancer therapy after CAR-T, end of data availability, or death (whichever occurred first). Outcomes included overall response rate to CAR-T (ORR: proportion of pts with physician-assessed complete/partial response [CR/PR]), proportion of pts with cytokine release syndrome (CRS) within 6 weeks and immune effector cell–associated neurotoxicity syndrome (ICANS) within 3 months after CAR-T, and were reported for the overall population, by CAR-T line, and by tafa/CAR-T treatment sequence. Results: A total of 338 pt charts (US: 168 [49.7%]; EU: 170 [50.3%]) were abstracted by 145 physicians (US: 73 [50.3%]; EU: 72 [49.7%]). Pts were 66.0% male with median (IQR) age 61.5 (55.1, 67.4) years at CAR-T infusion, 72.8% were primary refractory, and 53.0% had a revised International Prognostic Index score ≥3. CAR-T therapies administered (in 2L [n=37; all pts received tafa as bridging therapy to CAR-T], 3L [n=243], and 4L [n=58]) were axicabtagene ciloleucel (65.1%), lisocabtagene maraleucel (21.9%) and tisagenlecleucel (13.0%) Median (IQR) time from the last tafa dose until CAR-T was 1.2 (0.6-2.3) months; follow-up duration post CAR-T was 7.4 (3.3-10.6) months; and 73.1% of pts were still alive at the time of last contact. Overall, ORR for CAR-T among all pts was 81.1% (CR 58.6%, PR 22.5%). By CAR-T line, ORR was 91.9% (CR 59.5%, PR 32.4%) in 2L, 80.2% (CR 60.1%, PR 20.2%) in 3L, and 77.6% (CR 51.7%, PR 25.9%) in 4L. CRS and ICANS occurred in 30.8% (severe [grade ≥3], 7.4%) and 15.4% (severe [grade ≥3], 3.8%) of all pts, respectively. By line of CAR-T, respective incidences of CRS and ICANS were 24.3% (severe [grade ≥3], 5.4%) and 10.8% (all non-severe) in 2L, 29.6% (severe [grade ≥3], 7.4%) and 14.4% (severe [grade ≥3], 4.5%) in 3L, and 39.7% (severe [grade ≥3], 8.6%) and 22.4% (severe [grade ≥3], 3.4%) in 4L. Discussion: Findings from this large, global, real-world study demonstrated favorable effectiveness and safety outcomes with CAR-T therapy in pts with R/R DLBCL who were previously treated with tafa. These findings are particularly relevant in the context of the evolving DLBCL treatment landscape, including emerging front-line tafa data and the potential impact of prior tafa exposure on later-line treatment sequencing. Conclusion: While these real-world study findings should be interpreted in the context of an observational cohort, they support tafa followed by CAR-T therapy as a viable treatment sequencing strategy in clinical practice. Funding: Incyte Corporation.", "abstract_shown": true, "affiliations": [ "Division of Hematology and Hematologic Malignancies, Huntsman Cancer Institute, University of Utah, Salt Lake City, UT, United States", "Incyte Corporation, Wilmington, DE, United States", "Analysis Group, Inc., Montreal, QC, Canada", "Analysis Group, Inc., New York, NY, United States", "Hematology Department, Gregorio Marañón Hospital, Health Research Institute of Hospital General Universitario Gregorio Marañón, Madrid, Spain" ], "article_type": null, "arxiv": null, "author_total": 8, "authors": [ { "affs": [ 0 ], "name": "Narendranath EPPERLA" }, { "affs": [ 1 ], "name": "Kim SAVERNO" }, { "affs": [ 2 ], "name": "Irina PIVNEVA" }, { "affs": [ 3 ], "name": "Sakshi SETHI" }, { "affs": [ 1 ], "name": "Lucila SACKMANN" }, { "affs": [ 1 ], "name": "Andrea ZAFFALON" }, { "affs": [ 1 ], "name": "Julie WU" }, { "affs": [ 4 ], "name": "Mariana BASTOS-OREIRO" } ], "bibtex": "https://research.draconitic.com/paper/cbstj4aqfz991.bib", "cited_by": 0, "doi": "10.1016/j.htct.2026.107721", "fulltext_url": "http://www.sciencedirect.com/science/article/pii/S2531137926014689", "id": "cbstj4aqfz991", "issns": [ "2531-1379", "2531-1387" ], "landing_url": "https://doi.org/10.1016/j.htct.2026.107721", "language": "en", "licence": "CC-BY", "licence_label": "CC BY", "licence_source": "journal", "licence_url": "https://creativecommons.org/licenses/by/4.0/", "metadata_licence": null, "native_subjects": [ [ "lcc", "RC633-647.5" ], [ "openalex", "2730|CAR-T cell therapy research" ] ], "openalex": "W7223156536", "pdf_url": null, "pmcid": null, "pmid": null, "published": "2026-10-23", "publisher": "Elsevier", "ris": "https://research.draconitic.com/paper/cbstj4aqfz991.ris", "sources": [ { "first_seen": "2026-10-30T13:43:18Z", "native_id": "478f94c5a8dc4cd4936cf1d571698ede", "source": "doaj", "url": "https://doi.org/10.1016/j.htct.2026.107721" } ], "subjects": [ { "field": "medicine", "origin": "openalex:2730|CAR-T cell therapy research", "subfield": "oncology" } ], "title": "A REAL-WORLD STUDY OF THE EFFECTIVENESS AND SAFETY OF CHIMERIC ANTIGEN RECEPTOR T-CELL THERAPY FOLLOWING TAFASITAMAB IN PATIENTS WITH RELAPSED/REFRACTORY DIFFUSE LARGE B-CELL LYMPHOMA", "title_text": "A REAL-WORLD STUDY OF THE EFFECTIVENESS AND SAFETY OF CHIMERIC ANTIGEN RECEPTOR T-CELL THERAPY FOLLOWING TAFASITAMAB IN PATIENTS WITH RELAPSED/REFRACTORY DIFFUSE LARGE B-CELL LYMPHOMA", "type": "peer-reviewed", "updated_at": "2026-10-30T13:43:18Z", "url": "https://research.draconitic.com/paper/cbstj4aqfz991", "venue": "Hematology, Transfusion and Cell Therapy", "versions": [] }